GS vs PFE: Which Is the Better Buy?
Side-by-side comparison of The Goldman Sachs Group, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
The Goldman Sachs Group, Inc. · Financial Services
$926.55
-45.0% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
GS trades at a lower forward P/E
(15.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GS |
PFE |
| Current Price |
$926.55 |
$26.33 |
| Fair Value Estimate |
$509.60 |
$33.85 |
| Upside to Fair Value |
-45.0%
|
+28.6%
|
| Market Cap |
$275.0B |
$149.8B |
| Forward P/E |
15.6x
|
19.3x
|
| EV / EBITDA |
30.6x
|
12.9x
|
| Price / Sales |
2.5x
|
2.4x
|
| Price / FCF |
-5.8x
|
16.5x
|
| Revenue Growth YoY |
-45.4%
|
-1.2%
|
| Gross Margin |
55.5%
|
70.3%
|
| Operating Margin |
20.5%
|
24.7%
|
| Return on Equity |
14.6%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
6.06%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
The Goldman Sachs Group, Inc. operates as a leading global financial services firm specializing in investment banking, securities, investment management, and consumer banking. The company benefits from a high-quality business model characterized by strong brand recognition, deep client relationships, and a history of stable leadership. However, the stock is currently significantly overvalued, tra…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
GS |
PFE |
| Zone Low |
$382.20 |
$25.39 |
| Zone High |
$433.16 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|